Semmelweis University

Department of Pharmacology and Pharmacotherapy

Pharmahungary Group


Péter Ferdinandy

The Cardiovascular and metabolic research group focuses on molecular medicine of ischemic heart disease and cardioprotection in the presence of cardiovascular comorbidities.

Prof. Dr. Ferdinandy is also founder and CEO of a group of R&D companies Pharmahungary Group. Pharmahungary offers preclinical and clinical R&D in cardiometabolic diseases, and develops cardioprotective therapies and biomarkers.


  • Cell culture, isolated organs, and animal models in cardiovascular and metabolic diseases
  • In vivo imaging
  • Transcriptomics
  • Bioinformatics (network analysis)
  • Extracellular vesicles

Interested in collaborating on

Techniques, signalling mechanisms and other topics related to lncRNA. Also open to participate in different H2020 applications.

Selected publications on lncRNA

Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart
Perrino C, Barabási AL, Condorelli G, Davidson SM, De Windt LDimmeler S, Engel FB, Hausenloy DJ, Hill JA, Van Laake LW, Lecour S, Leor J, Madonna R, Mayr M, Prunier F, Sluijter JPG, Schulz R, Thum T, Ytrehus K, Ferdinandy PCardiovasc Res. 113(7):725-736, 2017.